Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Colourimetric Test for Chlamydia Detection in Sanitary Menstrual Products
FY 2024-25
Summary
This project will develop a novel diagnostic platform for Chlamydia trachomatis using CRISPR-Cas12a technology. C. trachomatis is the most common bacterial sexually transmitted infection (STI), often asymptomatic, and untreated cases can lead to severe complications such as pelvic inflammatory disease and infertility. While nucleic acid amplification tests (NAATs) like PCR are highly sensitive, their cost and laboratory requirements limit accessibility in resource-limited settings and inexpensive antigen-based tests lack sensitivity. Menstrual blood can be used to accurately detect chlamydia, providing an opportunity for at-home STI testing using sanitary products.This project aims to design a CRISPR-responsive hydrogel diagnostic system capable of specifically detecting C. trachomatis DNA and producing a simple, user-friendly colourimetric readout. The project will first use synthetic biology to design a one-pot reaction including DNA amplification and CRISPR-Cas12a detection to target conserved chromosomal and plasmidC. trachomatis DNA. This assay will be optimized for sensitivity and specificity before then being incorporated into a hydrogel-based lateral flow strip, producing a visible colour change for easy interpretation. Validation will involve testing with cultured isolates and clinical samples, and by assessing cross-reactivity with Neisseria gonorrhoeae. This work addresses key barriers to STI testing, such as stigma, privacy concerns, and limited access, providing an affordable, accessible, and equipment-free diagnostic tool. By embedding this technology into menstrual products, the work has the potential to transform at-home STI screening and promote sexual health equity globally.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529957
Name
Allan Raegan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Colourimetric Test for Chlamydia Detection in Sanitary Menstrual Products
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cas12a; Chlamydia Trachomatis; Crispr; Diagnostic; Hydrogel; Lateral Flow Strip; Nucleic Acid Amplification Test; Sexually Transmitted Infections; Stimuli-Responsive Materials
Abstract
This project will develop a novel diagnostic platform for Chlamydia trachomatis using CRISPR-Cas12a technology. C. trachomatis is the most common bacterial sexually transmitted infection (STI), often asymptomatic, and untreated cases can lead to severe complications such as pelvic inflammatory disease and infertility. While nucleic acid amplification tests (NAATs) like PCR are highly sensitive, their cost and laboratory requirements limit accessibility in resource-limited settings and inexpensive antigen-based tests lack sensitivity. Menstrual blood can be used to accurately detect chlamydia, providing an opportunity for at-home STI testing using sanitary products.This project aims to design a CRISPR-responsive hydrogel diagnostic system capable of specifically detecting C. trachomatis DNA and producing a simple, user-friendly colourimetric readout. The project will first use synthetic biology to design a one-pot reaction including DNA amplification and CRISPR-Cas12a detection to target conserved chromosomal and plasmidC. trachomatis DNA. This assay will be optimized for sensitivity and specificity before then being incorporated into a hydrogel-based lateral flow strip, producing a visible colour change for easy interpretation. Validation will involve testing with cultured isolates and clinical samples, and by assessing cross-reactivity with Neisseria gonorrhoeae. This work addresses key barriers to STI testing, such as stigma, privacy concerns, and limited access, providing an affordable, accessible, and equipment-free diagnostic tool. By embedding this technology into menstrual products, the work has the potential to transform at-home STI screening and promote sexual health equity globally.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Allan, Raegan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~